FNY Investment Advisers, LLC Q4 2022 vs. Q1 2023 13F Holdings Comparison

Investment management firms are required to submit a 13F form to the Securities and Exchange Commission (SEC) every quarter that provides details about their recent investment holdings. By analyzing these forms, we get a comprehensive view of the buying and selling patterns and investment strategies of these firms. FNY Investment Advisers' Q4 2022 and Q1 2023 13F filings indicate that the firm has made some significant changes to their investment portfolio. In this blog post, we will explore these changes and their potential implications.

One noteworthy change is FNY's increased position in Oak Street Health Ord (OSH). In Q4 2022, FNY did not hold any shares in the company, but in Q1 2023, they held 211,646 shares worth $8,186,000. Oak Street Health is a rapidly growing primary care provider for adults on Medicare in the United States. Its unique approach to senior care has attracted investment from various institutions. FNY's increased investment in OSH suggests that they see it as a promising growth opportunity.

FNY also increased its position in BYRNA Technologies Ord (BYRN) from 670,890 shares in Q4 2022 to 773,052 shares in Q1 2023, indicating a 11.6% increase in their investment. BYRN is a leading manufacturer of non-lethal personal protection devices used by law enforcement and civilians. The company has experienced strong growth in sales and is expanding geographically. FNY's increased investment indicates that they are optimistic about BYRN's future growth and market position.

Another company that caught FNY's eye was Horizon Therapeutics Public Ord (HZNP). In Q4 2022, FNY held 2,000 shares of the pharmaceutical company, which significantly increased to 58,872 shares worth $6,425,000 in Q1 2023. HZNP develops innovative medicines to treat rare and rheumatic diseases, including gout and thyroid eye disease. Horizon's Q4 2022 earnings report demonstrated strong revenue growth and beat analysts' estimates. FNY's increased position in HZNP indicates their confidence in the company's future performance.

FNY also acquired a stake in Vodafone Group ADR Rep 10 Ord (VOD) between Q4 2022 and Q1 2023. In Q4 2022, FNY held 60,000 shares, which significantly increased to 333,820 shares worth $3,685,000 in Q1 2023. VOD is a multinational telecommunications company and one of the largest mobile network operators worldwide. Recently, Vodafone's operations in Europe showed improvement with revenues growing and losses reducing. FNY's increase in VOD investment indicates their confidence in the company's potential for future growth.

In conclusion, FNY Investment Advisers made significant changes to its investment holdings between Q4 2022 and Q1 2023. Their purchase of Oak Street Health Ord, BYRNA Technologies Ord, Horizon Therapeutics Public Ord, and Vodafone Group ADR Rep 10 Ord signal FNY's interest in companies with promising growth potential and market positions. Their moves also suggest their carefully curated portfolio and investment strategy that aligns with the firm's objectives and goals. The SEC 13F filings are an essential tool for investors to keep a pulse on the changing strategies of large investment firms.